Takeda has localized production at Biocad facilities

03 April 2019

Takeda completed the localization of the production of Advate (Octocog alpha) medicine, intended for the treatment of patients with hemophilia A, at the Moscow-based Biocad plant. This was told to Kommersant in the Japanese company. They explained that the parties had organized the release of the finished dosage form of the medicine, as well as the primary packaging. The parties do not disclose the amount of investments in the localization.

Yaroslavl region

Investor profile

Takeda Pharmaceutical Company Limited


Company's website: www.takeda.com

T: +81-3-3278-3256

Public company

E-mail: jeffrey.cross@takeda.com

Contact: Christophe Weber, Representative Director

Takeda Pharmaceutical Company Limited (Takeda) is a research-based global company that primarily focuses on pharmaceuticals. Takeda has an active commercial presence in such therapeutic areas as central nervous system diseases, cardiovascular and metabolic diseases, gastroenterology, oncology and vaccines.  Takeda’s strong presence in North America, Japan and other Asian countries was further supplemented with good positions in Europe and rapidly growing emerging markets following its merger with Nycomed. The merged company is represented in more than 70 countries, ranks fifteenth among the biggest companies in the global pharmaceutical industry and has the world’s seventh largest portfolio of advanced developments.